Ranibizumab for treating diabetic macular oedema

TA274 Macular oedema (diabetic) - ranibizumab: review decision - April 2015 information

TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE decision paper - March 2015

TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE decision paper - March 2015 (PDF 68 KB)

TA274 Macular oedema (diabetic) - ranibizumab: review proposal - February 2015 information

TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE proposal paper February 2015

TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE proposal paper February 2015 (PDF 500 KB)

TA274 Macular oedema (diabetic) - ranibizumab: appendix A - matrix of stakeholders

TA274 Macular oedema (diabetic) - ranibizumab: appendix A - matrix of stakeholders (PDF 41 KB)

TA274 Macular oedema (diabetic) - ranibizumab: press release information

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination information

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination guidance

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination guidance (PDF 278 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 138 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): consultee and commentator comments on the ACD

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis (PDF 189 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK (PDF 67 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB (PDF 28 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD (PDF 14 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS (PDF 108 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health (PDF 8.3 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): comments on the ACD received from the public through the NICE website

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation document information

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): evaluation report

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): pre-meeting briefing

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): pre-meeting briefing (PDF 86 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Evidence Review Group report for NICE rapid review

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Evidence Review Group report for NICE rapid review (PDF 319 KB)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope